Background/Aims: This study tested the hypothesis that prevention of the development of hypertension, and not the class of antihypertensive agent, inhibits the increase in renal fibronectin and albuminuria in experimental diabetes. Methods: Four-week-old spontaneously hypertensive rats (SHR), with diabetes induced by streptozotocin, were randomized for no treatment, or treatment with captopril, amlodipine, an association of captopril and amlodipine (Cap+A) or an association of captopril and verapamil (Cap+V) for 12 weeks. Results: Systolic blood pressure increased similarly in control (187 B 5 mm Hg, mean B SE) and diabetic (186 B 4) SHR and was kept within the normal range by amlodipine (131 B 3), captopril (127 B 3), Cap+A (134 B 4) and Cap+V (134 B 9, p ! 0.0001). In diabetic rats, albuminuria was higher than in control SHR [geometric mean (variance), 1,213 (953-1,708) vs. 512 (213-850), p ! 0.0001] and was reduced to a similar extent by amlodipine [573 (353-744) Renal fibronectin increased in diabetic rats (24.0 B 3.3 densitometric units, mean B SE) compared to control rats (9.6 B 1.8, p = 0.0005) and was normalized by amlodipine (9.9 B 1.0, p = 0.0001), captopril (11.2 B 0.4, p = 0.0016), Cap+A (9.9 B 2.0, p = 0.0004) and Cap+V (14.7 B 4.9, p = 0.0159). Conclusion: In this model, tight blood pressure control rather than the class of antihypertensive agent was the main determinant factor in attenuating of nephropathy.
Introduction
Diabetic nephropathy is the leading cause of end-stage renal disease in many countries [1, 2] . In patients with diabetes mellitus (DM), a blood pressure reduction decreases the albumin excretion rate (AER) and the progression of renal dysfunction in patients with established renal disease [3] . In these scenarios, the use of antihypertensive drugs that act on the renin-angiotensin system (RAS) is more efficient than other classes of agents [4] [5] [6] [7] [8] , although this issue is still controversial [9] . The combina-tion of a non-dihydropyridine (non-DHP) calcium channel blocker with an angiotensin-converting enzyme (ACE) inhibitor reduces proteinuria to a greater extent than either agent alone in humans [10] [11] [12] and in animal models [13, 14] of diabetic renal disease.
Hypertension dramatically increases the urinary AER in spontaneously hypertensive rats (SHR) with streptozotocin (STZ)-induced DM [15] . The renoprotective effects of an ACE inhibitor in these rats were not superior to those observed with other antihypertensive agents [16, 17] . However, in these studies, the antihypertensive treatment was started when the rats were already hypertensive and the blood pressure did not normalize [16, 17] . The possibility that the albuminuria in diabetic SHR may vary depending on the antihypertensive agent used to prevent hypertension has not yet been investigated.
We recently reported that an increase in the abundance of renal fibronectin is an early phenomenon in diabetic SHR that is not seen in their diabetic genetically normotensive counterparts, Wistar-Kyoto (WKY) rats [18] . Fibronectin is a component of the extracellular matrix implicated in renal glomerulosclerosis [19, 20] . The usefulness of different antihypertensive agents in reducing renal fibronectin levels in diabetic SHR has not been studied.
The aim of this study was to test the hypothesis that prevention of the development of hypertension, and not the class of antihypertensive agent, is the main factor in attenuating experimental diabetic renal disease. We also examined whether the use of a non-DHP calcium channel blocker together with an ACE inhibitor would be more efficient than either agent alone in experimental diabetic renal disease. To address these questions, we compared the effect of preventing hypertension in young (4-weekold), pre-hypertensive SHR with STZ-induced diabetes using an ACE inhibitor, a dihydropyridine calcium channel blocker, a non-DHP calcium channel blocker or a combination of an ACE inhibitor with one of the two groups of calcium channel blocker by monitoring blood pressure, albuminuria and the expression of renal fibronectin.
Methods

Research Design
The protocols for this study complied with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Young, pre-hypertensive male SHR (4 weeks old), bred in our animal facility and derived from animals supplied by Taconic (Germantown, N.Y., USA) were used in the experiments. Diabetes was induced by injecting STZ (Sigma, St. Louis, Mo., USA) via a tail vein at a dose of 60 mg/kg after an overnight fast. The control group (control SHR, n = 10) received only vehicle (citrate buffer, pH 4.5). Glucose levels were determined in tail blood after 48 h and rats with blood glucose levels 1 15 mmol/l were used. The rats were randomized to receive no treatment (DM SHR, n = 10), captopril (Bristol-Meyers Squibb Brazil S/A, São Paulo, Brazil) at a concentration of 300 mg/l (DM+Cap, n = 8), amlodipine (Pfizer Laboratories Ltda, São Paulo, Brazil) at 50 mg/l (DM+A, n = 10), captopril plus amlodipine at 150 and 25 mg/l, respectively (DM Cap+A, n = 10), or captopril plus verapamil (BASF Pharma Ltda, Rio de Janeiro, Brazil) at 300 and 100 mg/l, respectively (DM Cap+V, n = 4), all administered in the drinking water. Based on the volume of liquid ingested in 24 h, the daily doses of the antihypertensive drugs were: amlodipine 10 mg/kg, captopril 100 mg/kg, captopril plus amlodipine 50 mg/kg and 5 mg/kg, and captopril plus verapamil 100 and 40 mg/kg, respectively. The doses of antihypertensive drugs were chosen based on a pilot study in which the drugs were tritated to obtain a blood pressure similar to that of the genetically normotensive controls (WKY rats) of the same age. At a dose of 280 mg/kg, verapamil did not significantly reduce the blood pressure levels in SHR (data not shown). To reduce mortality and maintain an environment appropriate for the development of diabetic renal disease, diabetic SHR were given 2 U of long-acting insulin (Novo Industri A/S, Copenhagen, Denmark) three times a week. All rats were housed in groups of four and fed normal rat chow containing 20% protein.
Parameters Determined
Body weight, systolic blood pressure (SBP), AER, and glomerular filtration rate (GFR) were determined at baseline and after 4, 8 and 12 weeks. The plasma glucose level was measured at baseline and after 12 weeks. The rats were killed at 12 weeks, the left kidney was quickly excised and weighed, the capsule was gently removed and a fragment of the renal cortex was separated to determine the expression of fibronectin [18] . Plasma glucose was measured by a glucose oxidase method (Merck, Darmstadt, Germany). SBP was determined in conscious, warmed rats by indirect tail-cuff plethysmography (Narco Biosystem, Houston, Tex., USA). AER was determined by single radial immunodiffusion [21] in urine collected from rats housed individually in metabolic cages for 24 h, as previously described [18] . The interassay coefficient of variation for this assay was 8.2% at a concentration of 20.7 Ìg/ml and the detection limit was 1.65 Ìg/ml [18] . The GFR was measured by single-injection isotopic technique using 51 Cr-EDTA [22] . In brief, 51 Cr-EDTA was injected via a tail vein and blood was sampled after 43 min. The plasma radioactivity was measured and compared with a reference prepared at the time of the injection. The GFR was then calculated from the plasma radioactivity and presented as ml/min/100 g b.w., as previously described [22] .
Western Blotting
Immunoblot analysis was done to determine fibronectin expression in renal cortices as previously described [18] . A fragment of the kidney cortex was homogenized at 4°C in buffer containing 30 mmol/l Tris-HCl, pH 7.5, 10 mmol/l EGTA, 5 mmol/l EDTA, 1 mmol/l dithothreitol, 250 mmol/l sucrose, 100 Ìg of PMSF/ml, and 1.9 Ìg of aprotinin/ml at a 10:1 ratio (v/v) of buffer to wet weight of tissue. After centrifugation for 10 min at 15,560 g at 4°C, an aliquot of the supernatant was separated for protein quantification by the Bradford method [23] using a Bio-Rad assay (Bio-Rad Laboratories, Lehfeld/Silveira/Ghini/Lopes de Faria Hercules, Calif., USA). The remaining supernatant was mixed with Laemmli sample buffer [24] , heated at 100°C for 5 min, and stored at -80°C for subsequent analysis. Ninety microliters of total protein from renal cortices were analyzed by SDS-PAGE in 6.5% gels followed by transfer to nitrocellulose membranes using a Mini Protean II Dual Slab Cell apparatus (Bio-Rad). The membrane was incubated for 1 h with the primary, goat anti-rat fibronectin antibody (Calbiochem-Novabiochem, La Jolen, Calif.., USA) at a dilution of 1:3,000 and then with the anti-goat secondary antibody conjugated to horseradish peroxidase (diluted 1:10,000) [18] . Protein bands were visualized using an enhanced chemiluminescence method (Super Signal CL-HPR Substrate System; Pierce, Rockford, Ill., USA) according to the manufacturer's protocol. The immunoreactive bands were scanned with a laser densitometer (Bio-Rad) and quantified with Multi-Analyst Macintosh software for image analysis systems (BioRad).
Statistical Analysis
The results are shown as the mean B SE, except for the AER, which are shown as geometric means and ranges. The AER were analyzed after logarithmic transformation. The data were compared by ANOVA using the StatView program (SAS Institute Inc., Cary, N.C., USA). Group means were compared using Fisher's least significant difference test. Differences in attained blood pressure levels with different antihypertensive drugs were also assessed as the area under the curve [25] and the results compared by Kruskal-Wallis. A p value ! 0.05 was considered statistically significant.
Results
Plasma Glucose, Body Weight and Kidney Weight
Plasma glucose levels in treated and non-treated diabetic rats were consistently elevated (115 mmol/l, p ! 0.0001) when compared to control SHR (F8 mmol/l), at baseline and week 12. Plasma glucose levels did not differ among the diabetic groups. Weight gain was lower in the diabetic rats compared to control SHR throughout the study (p ! 0.0001), but there was no significant difference in weight gain among the diabetic groups (DM SHR, DM+A, DM+Cap, DM Cap+A and DM Cap+V) ( fig. 1A,  table 1 ). The kidney to body weight ratio was higher (p ! 0.0001) in DM SHR compared to control SHR and was similar to DM SHR in the treated groups (table 1). fig. 1B ). The rise in SBP in non-treated rats was abolished to an equal extent in rats treated with amlodipine (131 B 3 mm Hg), captopril (127 B 3), captopril plus amlodipine (134 B 4) and captopril plus verapamil (134 B 9). Thus, SBP was kept within the normal range in the four diabetic treated groups during the 12 weeks of the study ( fig. 1B) . At any time point there was no difference (p 1 0.05) in attained blood pressure levels between treated rats, using either Fisher test or the area under the curve followed by Kruskal-Wallis. Figure 1C shows a progressive increase in the AER in non-treated DM SHR throughout the study which was greater than that observed in control SHR (p ! 0.0001). All antihypertensive therapies significantly reduced the AER compared to DM SHR during the study (p ! 0.0001). There was no difference in the AER among treated groups, except at week 4, when the AER in the amlodipine and captopril plus verapamil groups were significantly higher than in the other two groups (p ! 0.05). Normalization of the blood pressure with amlodipine, captopril, captopril plus amlodipine and captopril plus verapamil reduced the AER to non-diabetic SHR levels by the end of the study. At baseline, the GFR was similar in all studied groups, it increased significantly (p ! 0.05) in DM SHR compared to control SHR starting from 4 weeks' duration of diabetes (1.45 B 0.09 vs. 0.98 B 0.11; 1.57 B 0.25 vs. 0.96 B 0.11, and 1.47 B 0.24 vs. 0.71 B 0.12 ml/min/100 g, at 4, 8 and 12 weeks and diabetic and control SHR, respectively; fig. 1D ). Treatment with antihypertensive drugs did not modify the GFR in the diabetic rats ( fig. 1D ).
Renal Fibronectin Expression
The renal cortical expression of fibronectin in DM SHR was 2-to 3-fold higher than in control SHR (p = 0.0005). Treatment with amlodipine (p = 0.0001), captopril (p = 0.0016), captopril plus amlodipine (p = 0.0004) and captopril plus verapamil (p = 0.0159) significantly reduced fibronectin expression in renal cortices compared to DM SHR, but there were no significant differences among the reductions produced by the four therapies used ( fig. 2 ).
Discussion
Our results show that preventing the development of hypertension completely blunted the effect of hyperglycemia in elevating albuminuria and renal expression of fibronectin in a model of genetic hypertension with STZinduced DM. These effects occurred independently of the class of antihypertensive agents administered to the diabetic rats, i.e. an ACE inhibitor (captopril), dihydropyridine calcium channel blocker (amlodipine) or a combination of captopril plus amlodipine or captopril plus a nondihydropyridine calcium channel blocker (verapamil). These findings suggest that, in this model, tight and early blood pressure control rather than the class of antihypertensive agent is the main determinant in preventing the renal abnormalities induced by diabetes. The reduction in albuminuria and renal fibronectin expression in response to the prevention of hypertension occurred despite the severe hyperglycemia (115 mmol/l) in diabetic SHR, indicating that an elevated blood pressure was crucial for the development of the renal lesions induced by DM. These findings agree with our recent demonstration that the increased accumulation of fibronectin within the glomerulus 20 days after the induction of DM required the presence of both diabetes and hypertension [18] . This abnormal expression of renal fibronectin in diabetic SHR was not seen in diabetic genetically normotensive controls (WKY rats) or in non-diabetic hypertensive SHR.
Increased renal fibronectin expression is an early event in the pathogenesis of diabetic renal disease and its accumulation in the kidney is implicated in the development of glomerulosclerosis [19, 20] . The importance of hypertension in the development of albuminuria in SHR rats was originally described by Cooper et al. who showed that the AER in diabetic SHR was approximately ten times greater than in diabetic genetically normotensive WKY rats [15] . In patients with type 1 DM, elevated arterial pressure and microalbuminuria are early concomitant events in the development of diabetic renal disease [26] . Early intervention with antihypertensive drugs may be as efficient as glycemic control in preventing the progression of diabetic nephropathy [26] . Recent data from the UKPDS, a large epidemiological study, suggest that tight blood pressure control in patients with type 2 diabetes can be more effective than blood glucose control in reducing the frequency of micro-and macrovascular disease [27, 28] . These observations in humans agree with the experimental findings of the present study in which a non-glycemic intervention, i.e. blood pressure reduction, was an effective maneuver to ameliorate diabetic renal disease.
The interaction between genetic hypertension and hyperglycemia in elevating albuminuria and in increasing the accumulation of fibronectin in diabetic SHR is not fully understood. However, the mechanism likely involves generalized vasodilatation [29] , particularly vasodilatation of afferent arterioles, thereby allowing direct transmission of systemic hypertension to the glomerulus [30] . Increased intraglomerular pressure would activate several growth factors/cytokines, particularly TGF-ß, which would stimulate an increase in the formation of extracellular matrix components, including fibronectin [20] .
In patients with type 2 DM, the addition of a non-DHP calcium channel blocker (verapamil) to an ACE inhibitor significantly reduces the urinary albumin excretion compared to each inhibitor separately [10] . Animal studies also suggest a greater preservation of renal function when an ACE inhibitor is combined with a calcium channel blocker, compared to these agents separately at doses which produce similar levels of blood pressure reduction [13, 14] . However, in most of these studies, blood pressure levels were not normalized, i.e., SBP remained 1135 mm Hg. A recent study in patients with type 2 DM has demonstrated that the rate of progression from normo-to microalbuminuria or from microalbuminuria to overt proteinuria was significantly lower in patients with a mean blood pressure of 128/75 than in patients with a blood pressure of 137/81 mm Hg [31] . This effect was independent of the class of antihypertensive agent, an ACE inhibitor (enalapril) or calcium channel blocker (amlodipine), used to achieve the desired blood pressure levels [31] . It is possible that the early and aggressive intervention in arterial blood pressure in the rats studied here minimized the effect of a specific class of antihypertensive drugs.
Some studies have investigated the effects of different antihypertensive treatments on the renal lesions in diabetic SHR [16, 17, 32] . Cooper et al. [16, 17] compared the effects of ACE inhibition (enalapril or perindopril) with hydralazine and metoprolol or triple therapy (hydrochlorothiazide, reserpine and hydralazine) and concluded that although blood pressure reduction significantly ameliorated the renal disease in diabetic SHR, there was no specific benefit of ACE inhibition. More recently, the same group compared the effects of dual blockade of the RAS with an ACE inhibitor (captopril) and AT 1 antagonist (irbesartan) on the renal lesions in diabetic SHR and concluded that the combination of the two drugs reduced albuminuria more effectively than when either one was used separately [32] . However, since the blood pressure was significantly lower in the group receiving combination therapy, the authors were unable to distinguish between a specific effect of the two drugs and that attributable simply to a reduction in systemic blood pressure per se [32] . In this same study, the use of an AT 1 receptor antagonist (irbesartan), but not captopril, reduced the albuminuria and renal lesions in diabetic SHR, even though both drugs produced similar inhibition of the RAS and a comparable reduction in systemic arterial pressure and in the expression of renal TGF-ß 1 [32] .
As shown here, captopril, an ACE inhibitor, reduced the albuminuria and kidney fibronectin levels in diabetic SHR. Our study differed from those mentioned above in the early induction of diabetes to avoid a possible effect of established hypertension on kidney structure [33] , and in the precocious treatment of diabetes SHR with drugs that normalized the blood pressure to levels similar to those seen in genetically normotensive WKY rats. These results suggest that in diabetic SHR, tight and early blood pressure control is possibly more important than the class of antihypertensive agent in minimizing renal disease. Although caution must be exercised in extrapolating these data to humans, they do corroborate the concept that intensive and perhaps precocious treatment of blood pressure per se is an effective way of obtaining renal protection in patients with diabetic renal disease [3, 27, 28, 31] .
In summary, the prevention of hypertension in rats blunted the renal abnormalities induced by diabetes and hypertension. The renoprotective effect was independent of the class of antihypertensive agent administered. These findings may be relevant to interventions aimed at preventing diabetic renal disease in individuals predisposed to hypertension.
